研究单位：[1]Geneplus-Beijing Co. Ltd.[2]Peking Union Medical College Hospital[3]Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University,Changsha,Hunan,China[4]The First Affiliated Hospital of Xi'an Jiaotong University,Xi''an,Shaanxi,China[5]Sichuan Cancer Hospital,Chengdu,Sichuan,China[6]Affiliated Cancer Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China[7]Peking Union Medical College Hospital,Beijing,China[8]Peking University International Hospital,Beijing,China
研究目的：
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.
